SCHEMBL22970640

SCHEMBL22970640

COc1cc2c(cc1OC)C(C)N(CCS(C)(=O)=O)CC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA7 P43166 1/20 0.57
MAOA P21397 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.52
DHFR P00374 1/20 0.52
KMT2A Q03164 3/20 0.51
MEN1 O00255 1/20 0.51
BRD4 O60885 2/20 0.50
KCNN2 Q9H2S1 4/20 0.47
KCNN3 Q9UGI6 4/20 0.47
KCNN1 Q92952 2/20 0.47
LMNA P02545 1/20 0.46
MITF O75030 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
DRD2 P14416 1/20 0.44
DRD1 P21728 1/20 0.44
DRD3 P35462 1/20 0.44
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22782327 0.81 MAOA (0.67) CA7MAOASMN1; SMN2DHFRBRD4
SCHEMBL6369716 0.79 MAOA (0.63) CA7MAOASMN1; SMN2DHFRKMT2A
Veradoline SCHEMBL489286 0.77 MAOA (0.53) CA7MAOASMN1; SMN2DHFRKMT2A
Veradoline SCHEMBL29388371 0.77 MAOA (0.53) CA7MAOASMN1; SMN2DHFRKMT2A
SCHEMBL5289084 0.76 SMN1; SMN2 (0.61) CA7MAOASMN1; SMN2DHFRKMT2A
Veradoline SCHEMBL10656736 0.76 MAOA (0.55) CA7MAOASMN1; SMN2DHFRBRD4
Veradoline SCHEMBL125027 0.76 MAOA (0.55) CA7MAOASMN1; SMN2DHFRBRD4
SCHEMBL10662547 0.75 DHFR (0.53) CA7MAOASMN1; SMN2DHFRKMT2A
SCHEMBL3057030 0.75 CA2 (0.66) CA7MAOASMN1; SMN2DHFRKMT2A
SCHEMBL22970938 0.75 MAOA (0.57) CA7MAOASMN1; SMN2DHFRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210040066-A1 TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040066-A1 TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF PDE4B, PDE7B, PDE4A CA7 2495/4885MAOA 1442/4885SMN1; SMN2 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.